EPIRUS Biopharmaceuticals, Inc. 4
4 · EPIRUS Biopharmaceuticals, Inc. · Filed Jul 17, 2014
Insider Transaction Report
Form 4
Shea Thomas A.
Chief Financial Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2014-07-15+49,588→ 49,588 totalExercise: $1.30Exp: 2023-07-07→ Common Stock (49,588 underlying) - Award
Employee Stock Option (Right to Buy)
2014-07-15+93,608→ 93,608 totalExercise: $7.40Exp: 2024-04-14→ Common Stock (93,608 underlying)
Footnotes (4)
- [F1]BRunning, Inc., formerly a wholly owned subsidiary of the entity formerly known as Zalicus Inc., was merged with and into EPIRUS Pharmaceuticals, Inc., a privately held company (the "Predecessor"), on July 15, 2014 (the "Merger"). Following the Merger, Zalicus Inc. was renamed EPIRUS Biopharmaceuticals, Inc. These securities were received in the Merger in exchange for an employee stock option to acquire 374,000 shares of common stock of the Predecessor for $0.16 per share and reflect the 1 for 10 reverse stock split effected by the Issuer on July 16, 2014 (the "Stock Split").
- [F2]25% of the option shares vests on June 3, 2014 and the remaining option shares shall vest in substantially equal monthly installments over the remaining 3 years.
- [F3]These securities were received in the Merger in exchange for an employee stock option to acquire 706,000 shares of common stock of the Predecessor for $0.98 per share and gives effect to the Stock Split.
- [F4]25% of the option shares vests on April 15, 2015 and the remaining option shares shall vest in substantially equal monthly installments over the remaining 3 years.